Expert Blog
- Over the past six months we have had more questions than answers about the risk of incretin therapy (DPP-4 inhibitors and GLP-1 agonists) and the increased risks for both pancreatitis and pancreatic carcinoma. The discussion seems to have resolved to an interim and perhaps temporary conclusion based on the recent American Diabetes Association Scientific Sessions in Chicago in June.At that conference Dr.
Initial Combination Therapy in a Newly Diagnosed Patient
Posted July 25, 2013 by Doron Schneider, MD, FACPDoron Schneider, MD and Jack Leahy, MD discuss the treatment option of initial combination therapy in a newly diagnosed T2DM patient.
The Case for Bariatric Surgery as an Initial Treatment Option
Posted July 24, 2013 by John L. Leahy, MDDoron Schneider, MD and Jack Leahy, MD discuss the pros and cons of bariatric surgery as an initial treatment option.
Shared Decision Making
Posted June 25, 2013 by Joseph Largay, PA-C, CDEWith all the things I have to cover during my 20 minute follow-up visits with my patients with diabetes, I sometimes struggle with whether or not to interrupt as they tell me about something that, at first, seems irrelevant, at least to me.
I do, however, enjoy most of these discussions as I learn about their recent to Hawaii or some fishing trip. I do enjoy living vicariously through the lives of my patients!
Considering CAD Risk Factors in Treatment Decisions
Posted June 12, 2013 by John L. Leahy, MDDoron Schneider, MD and Jack Leahy, MD discuss the importance of patient BMI and other risk factors for coronary artery disease when weighing treatment options.
Listen to the podcast or read the transcript
Treatment Options for a Young, Newly Diagnosed Patient with a High BMI
Posted May 29, 2013 by John L. Leahy, MDDr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
A Newly Diagnosed T2DM Patient with a High BMI: Primary Care Perspective
Posted May 16, 2013 by Jay Shubrook, DO, FACOFP, FAAFPCase 6—A Newly Diagnosed Patient with a High BMI—is a very common scenario for the primary care physician. There are a number of issues worth highlighting before I outline my suggestions for treatment.
Initial Considerations
How the Affordable Care Act is Changing the Landscape of Diabetes
Posted March 19, 2013 by Doron Schneider, MD, FACPIt is certainly a new world. As a result of healthcare reform the landscape of diabetes care has forever been altered. The practicing clinician, patient and healthcare administrators all need to have a firm grasp of these new realities if they wish to prosper now and into the future. In this blog post I intend to provide a high level overview of the different ways that diabetes care is affected in this brave new world.Patients· Insurance coverage – patients will now be provided expanded insuranceA Partnership to Optimize Patient Health in Diabetes
Posted March 18, 2013 by Jay Shubrook, DO, FACOFP, FAAFPThere is almost no other disease as pervasive as type 2 diabetes, a disease that has touched almost every family in America. Although there was a time when we had limited management tools, we now have ten classes of medications plus many kinds of insulin available as options. The result is a choice of many treatment combinations, which, however welcome, can also be overwhelming for the practicing physician. With so many choices it becomes very hard to decide what comes after metformin.
Here We Go Again: Another New Therapy For Type 2 Diabetes
Posted January 17, 2013 by John L. Leahy, MD(Full disclosure – I am an Advisor to Janssen pharmaceuticals that makes canagliflozin)An FDA advisory panel last week reviewed canagliflozin, with the majority recommending approval. Canaglifozin is the first member of a new class of oral medications for type 2 diabetes–sodium-glucose co-transportor-2 (SGLT2) inhibitors–that will likely make it to the U.S. market.